TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA for MCL. However, development of relapses to BA is recognized with poor patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Vivian Changying, Hao, Dapeng, Jain, Preetesh, Li, Yijing, Cai, Qingsong, Yao, Yixin, Nie, Lei, Liu, Yang, Jin, Jingling, Wang, Wei, Lee, Heng-Huan, Che, Yuxuan, Dai, Enyu, Han, Guangchun, Wang, Ruiping, Rai, Kunal, Futreal, Andrew, Flowers, Christopher, Wang, Linghua, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513944/
https://www.ncbi.nlm.nih.gov/pubmed/36163179
http://dx.doi.org/10.1186/s12943-022-01655-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513944/
https://www.ncbi.nlm.nih.gov/pubmed/36163179
http://dx.doi.org/10.1186/s12943-022-01655-0

Ejemplares similares